{"id":556981,"date":"2021-08-10T18:12:02","date_gmt":"2021-08-10T18:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556981"},"modified":"2021-08-10T18:12:02","modified_gmt":"2021-08-10T18:12:02","slug":"radiation-dermatitis-market-insight-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/radiation-dermatitis-market-insight-epidemiology-and-market-forecast-2030_556981.html","title":{"rendered":"Radiation Dermatitis Market Insight, Epidemiology and Market Forecast – 2030"},"content":{"rendered":"
\n
\"Radiation<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Radiation Dermatitis Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of Radiation Dermatitis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n<\/div>\n

Radiation Dermatitis Market<\/strong><\/p>\n

TheRadiation Dermatitis market report<\/strong> <\/a>provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Radiation Dermatitis symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Radiation Dermatitis symptoms treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.<\/p>\n

Radiation Dermatitis Epidemiology<\/strong><\/p>\n

The Radiation Dermatitis symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.<\/p>\n

 <\/p>\n

Key Findings<\/p>\n

The total incident cases of Radiation Dermatitis are increasing by 7MM during the study period, i.e., 2018–2030.<\/p>\n

 <\/p>\n

The disease epidemiology covered in the report provides historical as well as forecasted Radiation Dermatitis symptoms epidemiology segmented as the Radiotherapy Utilization, Incidence of Radiation Dermatitis, Grade-specific cases of Radiation Dermatitis, and Treated cases of Radiation Dermatitis. The report includes Radiation Dermatitis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.<\/p>\n

Country-wise Radiation Dermatitis Epidemiology<\/strong><\/p>\n

The epidemiology segment also provides the Radiation Dermatitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n

 <\/p>\n

The total number of incident cases of Radiation Dermatitis associated in 7MM countries was 3,012,048 in 2020.<\/p>\n

Radiation Dermatitis Drug Chapters<\/strong><\/p>\n

The Radiation Dermatitis report’s drug chapter segment encloses the detailed analysis of Radiation Dermatitis’s early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Radiation Dermatitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.<\/p>\n

 <\/p>\n

Radiation Dermatitis Emerging Drug<\/strong><\/a><\/p>\n

 <\/p>\n

Tempol (APC-400): Adamis Pharmaceuticals\/Matrix Biomed<\/p>\n

Tempol, a superoxide dismutase-mimetic drug, has been shown to attenuate radical-induced damage, exerting beneficial effects in the animal models of oxidative stress and hypertension.<\/p>\n

 <\/p>\n

BMX-001: BioMimetix JV<\/p>\n

BMX-001 (MnTnBuOE-2-PyP5+) is a metalloporphyrin with differential action in response to radiation therapy and chemotherapy-induced oxidative stress. Early preclinical studies demonstrated BMX-001’s ability to act as a radioprotectant to healthy tissue such as a central nervous white matter and as a radiosensitizer to cancer cells, in particular, human glioblastoma xenografts.<\/p>\n

Products detail in the report…<\/p>\n

Radiation Dermatitis Market Outlook<\/strong><\/p>\n

The Radiation Dermatitis market outlook<\/strong> <\/a>helps build a detailed comprehension of the historical, current, and forecasted Radiation Dermatitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n

 <\/p>\n

This segment gives a thorough detail of Radiation Dermatitis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n

 <\/p>\n

According to DelveInsight, the Radiation Dermatitis market in 7MM is expected to grow in the study period 2018–2030.<\/p>\n

 <\/p>\n

Despite its prevalence, a gold standard does not exist for its prevention and management. Many of the currently used interventions are often based upon anecdotal evidence or physician preferences. It was observed that use of pharmacological interventions was at a lower end for prevention and treatment of RD as compared to other topical ointments and wound dressing options (Some of the most frequently used wound dressings include hydrocolloid or hydrogel dressings, soft silicone dressings, and silver-based dressings\/ointments.). Thus currently, there is a huge gap in the management of RD.<\/p>\n

 <\/p>\n

The RD market dynamics are anticipated to change during the forecasted period due to the expected launch of emerging therapies during the forecasted period of 2021–2030. There are presently two pipeline therapies under development for the prevention of Radiation Dermatitis (RD), namely Tempol (Matrix Biomed) and BMX-001 (BioMimetix).<\/p>\n

 <\/p>\n

Key Findings<\/p>\n

This section includes a glimpse of the Radiation Dermatitis market in the 7MM.<\/p>\n

 <\/p>\n

The market size of Radiation Dermatitis in the seven major markets was USD 210.5 million in 2020.<\/p>\n

 <\/p>\n

The United States Market Outlook<\/p>\n

This section provides the total Radiation Dermatitis market size and market size by therapies in the United States.<\/p>\n

 <\/p>\n

The United States accounts for the largest market size of Radiation Dermatitis compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.<\/p>\n

 <\/p>\n

EU-5 Countries: Market Outlook<\/p>\n

The total Radiation Dermatitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.<\/p>\n

 <\/p>\n

Japan Market Outlook<\/p>\n

The total Radiation Dermatitis market Size and market Size by therapies in Japan are also mentioned.<\/p>\n

Radiation Dermatitis Drugs Uptake<\/strong><\/p>\n

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Radiation Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. <\/p>\n

 <\/p>\n

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again help investigate factors important in the market uptake and in making financial and regulatory decisions.<\/p>\n

Request for sample pages @ Radiation Dermatitis Market size<\/a><\/strong><\/p>\n

Table of contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Report Introduction<\/p>\n

3. Radiation Dermatitis Market Overview at a Glance<\/p>\n

3.1. Market Share (%) Distribution of Radiation Dermatitis in 2018<\/p>\n

3.2. Market Share (%) Distribution of Radiation Dermatitis in 2030<\/p>\n

4. Executive Summary of Radiation Dermatitis<\/p>\n

5. Disease Background and Overview<\/p>\n

5.1. Introduction<\/p>\n

5.2. Pathophysiology<\/p>\n

5.3. Signs and Symptoms<\/p>\n

5.4. Risk Factors<\/p>\n

5.5. Types of Radiation Dermatitis (RD)<\/p>\n

5.6. Clinical manifestations<\/p>\n

5.7. Diagnosis<\/p>\n

5.8. Grading<\/p>\n

5.9. Differential Diagnosis<\/p>\n

5.10. Treatment<\/p>\n

5.10.1. Treatment of acute radiodermatitis<\/p>\n

5.10.2. Treatment of chronic radiodermatitis<\/p>\n

6. Epidemiology and Patient Population<\/p>\n

6.1. Key Findings<\/p>\n

6.2. 7MM Total Incident Population of Radiation Dermatitis<\/p>\n

6.3. Epidemiology of Radiation Dermatitis<\/p>\n

6.4. The United States<\/p>\n

6.4.1. Radiotherapy Utilization in the United States<\/p>\n

6.4.2. Incidence of Radiation Dermatitis in the United States<\/p>\n

6.4.3. Grade-specific cases of Radiation Dermatitis in the United States<\/p>\n

6.4.4. Treated cases of Radiation Dermatitis in the United States<\/p>\n

6.5. EU5<\/p>\n

6.5.1. Germany<\/p>\n

6.5.1.1. Radiotherapy Utilization in Germany<\/p>\n

6.5.1.2. Incidence of Radiation Dermatitis in Germany<\/p>\n

6.5.1.3. Grade-specific cases of Radiation Dermatitis in Germany<\/p>\n

6.5.1.4. Treated cases of Radiation Dermatitis in Germany<\/p>\n

6.5.2. France<\/p>\n

6.5.2.1. Radiotherapy Utilization in France<\/p>\n

6.5.2.2. Incidence of Radiation Dermatitis in France<\/p>\n

6.5.2.3. Grade-specific cases of Radiation Dermatitis in France<\/p>\n

6.5.2.4. Treated cases of Radiation Dermatitis in France<\/p>\n

6.5.3. Italy<\/p>\n

6.5.3.1. Radiotherapy Utilization in Italy<\/p>\n

6.5.3.2. Incidence of Radiation Dermatitis in Italy<\/p>\n

6.5.3.3. Grade-specific cases of Radiation Dermatitis in Italy<\/p>\n

6.5.3.4. Treated cases of Radiation Dermatitis in Italy<\/p>\n

6.5.4. Spain<\/p>\n

6.5.4.1. Radiotherapy Utilization in Spain<\/p>\n

6.5.4.2. Incidence of Radiation Dermatitis in Spain<\/p>\n

6.5.4.3. Grade-specific cases of Radiation Dermatitis in Spain<\/p>\n

6.5.4.4. Treated cases of Radiation Dermatitis in Spain<\/p>\n

6.5.5. United Kingdom<\/p>\n

6.5.5.1. Radiotherapy Utilization in the United Kingdom<\/p>\n

6.5.5.2. Incidence of Radiation Dermatitis in the United Kingdom<\/p>\n

6.5.5.3. Grade-specific cases of Radiation Dermatitis in the United Kingdom<\/p>\n

6.5.5.4.Treated cases of Radiation Dermatitis in the United Kingdom<\/p>\n

6.6. Japan<\/p>\n

6.6.1. Radiotherapy Utilization in the United States<\/p>\n

6.6.2. Incidence of Radiation Dermatitis in Japan<\/p>\n

6.6.3. Grade-specific cases of Radiation Dermatitis in Japan<\/p>\n

6.6.4. Treated cases of Radiation Dermatitis in Japan<\/p>\n

7. Organizations contributing towards Radiation Dermatitis<\/p>\n

8. Patient Journey<\/p>\n

9. Case Reports<\/p>\n

10. Emerging Therapies10.1 Key Cross Competition<\/p>\n

10.1. Key Competitor<\/p>\n

10.2. Tempol (APC-400): Adamis Pharmaceuticals\/Matrix Biomed<\/p>\n

10.2.1. Drug Description<\/p>\n

10.2.2. Regulatory Milestones<\/p>\n

10.2.3. Clinical Development<\/p>\n

10.2.4. Clinical Trials Information<\/p>\n

10.2.5. Safety and Efficacy<\/p>\n

10.2.6. Product Profile<\/p>\n

10.3. BMX-001: BioMimetix JV<\/p>\n

10.3.1. Drug Description<\/p>\n

10.3.2. Regulatory Milestones<\/p>\n

10.3.3. Clinical Development<\/p>\n

10.3.4. Clinical Trials Information<\/p>\n

10.3.5. Safety and Efficacy<\/p>\n

10.3.6. Product Profile<\/p>\n

11. Radiation Dermatitis: Seven Major Market Analysis<\/p>\n

11.1. Key Findings<\/p>\n

11.2. Market Size of Radiation Dermatitis in 7MM<\/p>\n

11.3. Market Outlook<\/p>\n

11.4. United States Market Size<\/p>\n

11.4.1. Total Market Size of Radiation Dermatitis in the United States<\/p>\n

11.4.2. Market Size of Radiation Dermatitis by Therapies in United States<\/p>\n

13.5. EU-5 Market Size<\/p>\n

11.5.1. Germany<\/p>\n

11.5.1.1. Total Market size of Radiation Dermatitis in Germany<\/p>\n

11.5.1.2. Market Size of Radiation Dermatitis by Therapies in Germany<\/p>\n

11.5.2. France<\/p>\n

11.5.2.1. Total Market size of Radiation Dermatitis in France<\/p>\n

11.5.2.2. Market Size of Radiation Dermatitis by Therapies in France<\/p>\n

11.5.3. Italy<\/p>\n

11.5.3.1. Total Market size of Radiation Dermatitis in Italy<\/p>\n

11.5.3.2. Market Size of Radiation Dermatitis by Therapies in Italy<\/p>\n

11.5.4. Spain<\/p>\n

11.5.4.1. Total Market size of Radiation Dermatitis in Spain<\/p>\n

11.5.4.2. Market Size of Radiation Dermatitis by Therapies in Spain<\/p>\n

11.5.5. United Kingdom<\/p>\n

11.5.5.1.Total Market size of Radiation Dermatitis in the United Kingdom<\/p>\n

11.5.5.2. Market Size of Radiation Dermatitis by Therapies in the United Kingdom<\/p>\n

11.6. Japan<\/p>\n

11.6.1. Total Market size of Radiation Dermatitis in Japan<\/p>\n

11.6.2. Market Size of Radiation Dermatitis by Therapies in Japan<\/p>\n

12. KOL Views<\/p>\n

13. Market Drivers<\/p>\n

14. Market Barriers<\/p>\n

15. SWOT Analysis<\/p>\n

16. Unmet Needs<\/p>\n

17. Market Access<\/p>\n

18. Appendix<\/p>\n

18.1. Bibliography<\/p>\n

18.2. Report Methodology<\/p>\n

19. DelveInsight Capabilities<\/p>\n

20. Disclaimer<\/p>\n

21. About DelveInsight<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Radiation Dermatitis Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of Radiation Dermatitis in the United States, EU5 (Germany, Spain, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-556981","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556981"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556981\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}